Urologic oncologyHumansUrinary Bladder NeoplasmsOrganoidsImmunohistochemistryCisplatin
Molecular subtyping of advanced bladder cancer patients and patient-derived organoids based on a 3-marker immunohistochemistry approach to evaluate chemotherapy sensitivity.
Bastiaan J Viergever, Alba C Zuidema, Trudy Jonges, Susanne J Van Schelven, Denise Westland, Eric Kalkhoven, Onno Kranenburg, Richard P Meijer
Published: 202610.1016/j.urolonc.2025.09.023
Abstract
BACKGROUND: Bladder cancer is among the top ten most common cancers globally and one of the most expensive to treat, primarily due to high recurrence rates stemming from significant heterogeneity and mutational rates. The standard treatment, cisplati…
Preview only. Read the full abstract at the source